Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 11 Apr 2015 |
| Zealand convenes for the Annual General Meeting 2015 | 26 Mar 2015 |
| Zealand announces the grant of warrants under existing warrant scheme | 25 Mar 2015 |
| Zealand announces an amendment to its Articles of Association to reflect grant of warrants | 25 Mar 2015 |
| CORRECTION: Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants | 24 Mar 2015 |
| Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants | 24 Mar 2015 |